Baxalta Shire Merger Agreement

The deal comes after Reuters first reported on Dec. 22 that Shire`s latest bid for Baxalta met Baxalta`s valuation expectations. This would be one of the largest mergers in the healthcare sector in 2016. Baxalta said the Shire merger termination fee was $369 million. The closing of the merger between Shire and Baxalta comes a week after shareholders of both companies voted to approve the deal. Shire and Baxalta announced their merger plans in January, with Shire saying it expected to achieve more than $500 million in cost reductions or “synergies” in the first 3 years after the deal closes. “A lot of people don`t like the deal,” especially because of its addiction to Baxalta`s hemophilia franchise, said John Boris, an analyst at Suntrust Robinson Humphrey. “Today, when we create our combined company, we have a talented and experienced extended management team that guides the organization in achieving our goals,” added Dr. Ornskov.

. . .

Comments are closed.